Copyright
©The Author(s) 2015.
World J Gastroenterol. Nov 28, 2015; 21(44): 12660-12666
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12660
Published online Nov 28, 2015. doi: 10.3748/wjg.v21.i44.12660
Population characteristics (n= 106) | Value |
Male gender | 47 (44) |
Age - mean | 40 ± 13 yr |
Median time between diagnosis and VCE | 5.5 (IQR 2-10) yr |
Montreal classification | |
Age at diagnosis | |
A1: Below 17 | 7 (7) |
A2: 17-40 | 84 (79) |
A3: Above 40 | 15 (14) |
Behavior | |
B1: Non-stenosing/non-penetrating | 86 (81) |
B2: Stenosing | 12 (11) |
B3: Penetrating | 8 (8) |
Location | |
L1: Terminal ileum | 74 (70) |
L2: Colonic | 10 (9) |
L3: Ileocolonic | 22 (21) |
+ L4: Upper disease | 38 (36) |
Treatment before VCE | |
Anti-TNF | 21 (20) |
Immunosuppressors | 38 (36) |
Aminosalicylates only | 40 (38) |
No treatment | 7 (6) |
- Citation: Santos-Antunes J, Cardoso H, Lopes S, Marques M, Nunes AC, Macedo G. Capsule enteroscopy is useful for the therapeutic management of Crohn’s disease. World J Gastroenterol 2015; 21(44): 12660-12666
- URL: https://www.wjgnet.com/1007-9327/full/v21/i44/12660.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i44.12660